Publications
Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clinical lymphoma, myeloma & leukemia. 2020. PMID: 33288485
Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clinical lymphoma, myeloma & leukemia. 2020. PMID: 33288485
Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. CA: a cancer journal for clinicians. 2020. PMID: 33165928
Mazie Tsang, Joseph Cleveland, Miguel Carlos Cerejo, Huimin Geng, James L. Rubenstein. Survival and Patient-Reported Outcomes of Older Adults with Primary Central Nervous System Lymphoma on Low-Dose Lenalidomide. Blood. 2020. PMID:
Alexander E. Perl, Jessica K. Altman, Naoko Hosono, Pau Montesinos, Nikolai A. Podoltsev, Giovanni Martinelli, Catherine C. Smith, Mark Levis, Christoph Röllig, Marco Groß-Langenhoff, Nahla Hasabou, Qiaoyang Lu, Ramon V. Tiu. Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. Blood. 2020. PMID:
Kelly L. Schoenbeck, Sirisha Tummala, Neha G. Goyal, Catherine C. Smith, Neil P. Shah. Cognitive Dysfunction Associated with Tyrosine Kinase Inhibitors in Patients with CML in Chronic Phase. Blood. 2020. PMID:
Eytan M. Stein, Ying Huang, Uma Borate, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark Litzow, Tara Lin, Prapti A. Patel, Matthew C Foster, Michael Boyiadzis, Robert H. Collins, Jo-Anne Vergilio, Nyla A Heerema, Leonard Rosenberg, Ashley Owen Yocum, Timothy Chen, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Jordan Chervin, Abigail Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Alice S. Mims. Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial. Blood. 2020. PMID:
Amir T. Fathi, Alexander E. Perl, Mark Levis, Catherine C. Smith, Andrew M. Brunner, Koichi Takahashi, Philip C. Amrein, Hanno R. Hock, Gabriela S. Hobbs, Rupa Narayan, Jenna A. Moran, Meghan Bergeron, Julia E. Foster, Naval Daver, Courtney D. DiNardo. Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML). Blood. 2020. PMID:
Naval Daver, Jessica K. Altman, Joseph Maly, Mark Levis, Ellen Ritchie, Mark Litzow, James K. McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Wan-Jen Hong, Bo Tong, Qin Qin, Kimberley Dilley, Alexander E. Perl. Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study. Blood. 2020. PMID:
Kelly L. Schoenbeck, Sirisha Tummala, Rebecca L. Olin, Neha G. Goyal, Anand Dhruva, Lloyd E. Damon, Aaron C. Logan, Catherine C. Smith, Neil P. Shah. Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance. Blood. 2020. PMID:
Kelly L. Schoenbeck, Sirisha Tummala, Rebecca L. Olin, Neha G. Goyal, Anand Dhruva, Lloyd E. Damon, Aaron C. Logan, Catherine C. Smith, Neil P. Shah. Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance. Blood. 2020. PMID:
Borno HT, Odisho AY, Gunn CM, Pankowska M, Rider JR. Disparities in precision medicine-Examining germline genetic counseling and testing patterns among men with prostate cancer. Urologic oncology. 2020. PMID: 33158741
Hultcrantz M, Richter J, Rosenbaum CA, Patel D, Smith EL, Korde N, Lu SX, Mailankody S, Shah UA, Lesokhin AM, Hassoun H, Tan C, Maura F, Derkach A, Diamond B, Rossi A, Pearse R, Madduri D, Chari A, Kaminetzky D, Braunstein MJ, Gordillo C, Reshef R, Taur Y, Davies FE, Jagannath S, Niesvizky R, Lentzsch S, Morgan GJ, Landgren O. Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood cancer discovery. 2020. PMID: 34661147
Kaufman JL, Dimopoulos MA, White D, Benboubker L, Cook G, Leiba M, Morton J, Joy Ho P, Kim K, Takezako N, Moreau P, Sutherland HJ, Magen H, Iida S, Kim JS, Miles Prince H, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Trivedi S, Casneuf T, Krevvata M, Ukropec J, Kobos R, Avet-Loiseau H, Usmani SZ, San-Miguel J. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood cancer journal. 2020. PMID: 33149130
Kazemi S, Kawaguchi S, Badr CE, Mattos DR, Ruiz-Saenz A, Serrill JD, Moasser MM, Dolan BP, Paavilainen VO, Oishi S, McPhail KL, Ishmael JE. Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A. Biochemical pharmacology. 2020. PMID: 33152346
Luo MM, Usmani SZ, Mateos MV, Nahi H, Chari A, San-Miguel J, Touzeau C, Suzuki K, Kaiser M, Carson R, Heuck C, Qi M, Zhou H, Sun YN, Parasrampuria DA. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. Journal of clinical pharmacology. 2020. PMID: 33145788
Mmbaga EJ, Mushi BP, Deardorff K, Mgisha W, Akoko LO, Paciorek A, Hiatt RA, Buckle GC, Mwaiselage J, Zhang L, Van Loon K. A Case-Control Study to Evaluate Environmental and Lifestyle Risk Factors for Esophageal Cancer in Tanzania. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2020. PMID: 33144280
Mmbaga EJ, Mushi BP, Deardorff K, Mgisha W, Akoko LO, Paciorek A, Hiatt RA, Buckle GC, Mwaiselage J, Zhang L, Van Loon K. A Case-Control Study to Evaluate Environmental and Lifestyle Risk Factors for Esophageal Cancer in Tanzania. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2020. PMID: 33144280
Mmbaga EJ, Mushi BP, Deardorff K, Mgisha W, Akoko LO, Paciorek A, Hiatt RA, Buckle GC, Mwaiselage J, Zhang L, Van Loon K. A Case-Control Study to Evaluate Environmental and Lifestyle Risk Factors for Esophageal Cancer in Tanzania. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2020. PMID: 33144280
Gomez SL, Washington SL, Cheng I, Huang FW, Cooperberg MR. Monitoring Prostate Cancer Incidence Trends: Value of Multiple Imputation and Delay Adjustment to Discern Disparities in Stage-specific Trends. European urology. 2020. PMID: 33153814